

# Lorazepam

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878  
Issue date: 31/01/2023 Version: 1.0

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1. Product identifier

Product form : Substance  
Substance name : Lorazepam  
Product code : 201600536  
Synonyms : Lorazepam, salts, hydrates, isomers and impurities where applicable

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against

##### 1.2.1. Relevant identified uses

Main use category : The product is intended for research, analysis and scientific education.  
Use of the substance/mixture : For professional use only  
Function or use category : Laboratory chemicals

##### 1.2.2. Uses advised against

Restrictions on use : Do not use : Ingestion, Inhalation, Dermal

#### 1.3. Details of the supplier of the safety data sheet

European Directorate for the Quality of Medicines & Healthcare  
EDQM, Council of Europe 7, Allée Kastner, CS30026  
F- 67081 Strasbourg  
France  
T +33(0)388412035 - F +33(0)388412771  
[sds@edqm.eu](mailto:sds@edqm.eu) - [www.edqm.eu](http://www.edqm.eu)

#### 1.4. Emergency telephone number

Emergency number : +33(0)390215608

### SECTION 2: Hazards identification

#### 2.1. Classification of the substance or mixture

##### Classification according to Regulation (EC) No. 1272/2008 [CLP]

Reproductive toxicity, Category 2	H361
Reproductive toxicity, Additional category, Effects on or via lactation	H362
Specific target organ toxicity – Single exposure, Category 3, Narcosis	H336
Full text of H- and EUH-statements: see section 16	

##### Adverse physicochemical, human health and environmental effects

Expert judgement and weight of evidence determination.

#### 2.2. Label elements

##### Labelling according to Regulation (EC) No. 1272/2008 [CLP]

Hazard pictograms (CLP) :



GHS07

GHS08

Signal word (CLP) : Warning  
Hazard statements (CLP) : H336 - May cause drowsiness or dizziness.  
H361d - Suspected of damaging the unborn child.  
Precautionary statements (CLP) : P202 - Do not handle until all safety precautions have been read and understood.  
P261 - Avoid breathing dust.  
P308+P313 - IF exposed or concerned: Get medical advice/attention.

Labelling according to: exemption for inner packaging where the contents do not exceed 10ml

# Lorazepam

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

Hazard pictograms (CLP)

:



GHS08

### 2.3. Other hazards

No additional information available

## SECTION 3: Composition/information on ingredients

### 3.1. Substances

Name	Product identifier	%	Classification according to Regulation (EC) No. 1272/2008 [CLP]
Lorazepam	-	≤ 100	Repr. 2, H361 Lact., H362 STOT SE 3, H336

Full text of H- and EUH-statements: see section 16

### 3.2. Mixtures

Not applicable

## SECTION 4: First aid measures

### 4.1. Description of first aid measures

First-aid measures after skin contact : Wipe off as much as possible (using a clean, soft, absorbent material).  
First-aid measures after eye contact : Rinse eyes with water as a precaution.

### 4.2. Most important symptoms and effects, both acute and delayed

No additional information available

### 4.3. Indication of any immediate medical attention and special treatment needed

No additional information available

## SECTION 5: Firefighting measures

### 5.1. Extinguishing media

Suitable extinguishing media : Extinguishing blanket.

### 5.2. Special hazards arising from the substance or mixture

Fire hazard : See Heading 2.2.

### 5.3. Advice for firefighters

Firefighting instructions : Use extinguishing media appropriate for surrounding fire.

# Lorazepam

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### SECTION 6: Accidental release measures

#### 6.1. Personal precautions, protective equipment and emergency procedures

##### 6.1.1. For non-emergency personnel

Emergency procedures : Avoid all unnecessary exposure.

##### 6.1.2. For emergency responders

No additional information available

#### 6.2. Environmental precautions

No additional information available

#### 6.3. Methods and material for containment and cleaning up

No additional information available

#### 6.4. Reference to other sections

No additional information available

### SECTION 7: Handling and storage

#### 7.1. Precautions for safe handling

No additional information available

#### 7.2. Conditions for safe storage, including any incompatibilities

No additional information available

#### 7.3. Specific end use(s)

See Heading 1.

### SECTION 8: Exposure controls/personal protection

#### 8.1. Control parameters

##### 8.1.1 National occupational exposure and biological limit values

No additional information available

##### 8.1.2. Recommended monitoring procedures

No additional information available

##### 8.1.3. Air contaminants formed

No additional information available

##### 8.1.4. DNEL and PNEC

No additional information available

##### 8.1.5. Control banding

No additional information available

#### 8.2. Exposure controls

##### 8.2.1. Appropriate engineering controls

###### Appropriate engineering controls:

Keep in a well-ventilated room. Both local exhaust and general room ventilation are usually required.

##### 8.2.2. Personal protection equipment

###### 8.2.2.1. Eye and face protection

No additional information available

# Lorazepam

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### 8.2.2.2. Skin protection

#### Skin and body protection:

Lab coat

#### Hand protection:

Protective gloves

### 8.2.2.3. Respiratory protection

No additional information available

### 8.2.2.4. Thermal hazards

No additional information available

### 8.2.3. Environmental exposure controls

No additional information available

## SECTION 9: Physical and chemical properties

### 9.1. Information on basic physical and chemical properties

Physical state	: Solid
Colour	: Not available
Appearance	: Powder.
Odour	: Not available
Odour threshold	: Not available
Melting point	: Not available
Freezing point	: Not available
Boiling point	: Not available
Flammability	: Not available
Explosive limits	: Not applicable
Lower explosion limit	: Not applicable
Upper explosion limit	: Not applicable
Flash point	: Not applicable
Auto-ignition temperature	: Not applicable
Decomposition temperature	: Not available
pH	: Not available
pH solution	: Not available
Viscosity, kinematic	: Not applicable
Solubility	: Water: < 0.1 g/l
Partition coefficient n-octanol/water (Log Kow)	: Not available
Vapour pressure	: Not available
Vapour pressure at 50°C	: Not available
Density	: Not available
Relative density	: Not available
Relative vapour density at 20°C	: Not applicable
Particle size	: Not available

### 9.2. Other information

#### 9.2.1. Information with regard to physical hazard classes

No additional information available

#### 9.2.2. Other safety characteristics

No additional information available

## SECTION 10: Stability and reactivity

### 10.1. Reactivity

Stable under normal conditions.

# Lorazepam

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### 10.2. Chemical stability

No additional information available

### 10.3. Possibility of hazardous reactions

None known.

### 10.4. Conditions to avoid

No additional information available

### 10.5. Incompatible materials

None under normal use. See Section 7.

### 10.6. Hazardous decomposition products

When heated to decomposition, emits dangerous fumes.

## SECTION 11: Toxicological information

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute toxicity (oral) : Not classified (Based on available data, the classification criteria are not met)  
Acute toxicity (dermal) : Not classified (Lack of data)  
Acute toxicity (inhalation) : Not classified (Lack of data)

#### Lorazepam

LD50 oral rat	4500 mg/kg
Skin corrosion/irritation	: Not classified (Lack of data)
Serious eye damage/irritation	: Not classified (Lack of data)
Respiratory or skin sensitisation	: Not classified (Lack of data)
Germ cell mutagenicity	: Not classified (Lack of data)
Carcinogenicity	: Not classified (Lack of data)
Reproductive toxicity	: Suspected of damaging fertility or the unborn child. May cause harm to breast-fed children.
STOT-single exposure	: May cause drowsiness or dizziness.
STOT-repeated exposure	: Not classified (Lack of data)
Aspiration hazard	: Not classified (Technical impossibility to obtain the data)

### 11.2. Information on other hazards

No additional information available

## SECTION 12: Ecological information

### 12.1. Toxicity

Ecology - general : Presents no specific risk for the environment.  
Hazardous to the aquatic environment, short-term (acute) : Not classified (Based on available data, the classification criteria are not met)  
Hazardous to the aquatic environment, long-term (chronic) : Not classified (Lack of data)

#### Lorazepam

LC50 - Fish [1]	500 mg/l (24h, Oncorhynchus mykiss (Rainbow trout))
-----------------	-----------------------------------------------------

### 12.2. Persistence and degradability

No additional information available

### 12.3. Bioaccumulative potential

No additional information available

# Lorazepam

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### 12.4. Mobility in soil

No additional information available

### 12.5. Results of PBT and vPvB assessment

No additional information available

### 12.6. Endocrine disrupting properties

No additional information available

### 12.7. Other adverse effects

No additional information available

## SECTION 13: Disposal considerations

### 13.1. Waste treatment methods

No additional information available

## SECTION 14: Transport information

In accordance with ADR / IMDG / IATA

ADR	IMDG	IATA
<b>14.1. UN number or ID number</b>		
Not applicable	Not applicable	Not applicable
<b>14.2. UN proper shipping name</b>		
Not applicable	Not applicable	Not applicable
<b>14.3. Transport hazard class(es)</b>		
Not applicable	Not applicable	Not applicable
<b>14.4. Packing group</b>		
Not applicable	Not applicable	Not applicable
<b>14.5. Environmental hazards</b>		
Not applicable	Not applicable	Not applicable
No supplementary information available		

### 14.6. Special precautions for user

#### Overland transport

Not applicable

#### Transport by sea

Not applicable

#### Air transport

Not applicable

### 14.7. Maritime transport in bulk according to IMO instruments

Not applicable

# Lorazepam

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### SECTION 15: Regulatory information

#### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

##### 15.1.1. EU-Regulations

###### REACH Annex XVII (Restriction List)

Not listed on REACH Annex XVII

###### REACH Annex XIV (Authorisation List)

Not listed on REACH Annex XIV (Authorisation List)

###### REACH Candidate List (SVHC)

Not listed on the REACH Candidate List

###### PIC Regulation (Prior Informed Consent)

Not applicable.

###### POP Regulation (Persistent Organic Pollutants)

Not applicable.

###### Ozone Regulation (1005/2009)

Not listed on the Ozone Depletion list (Regulation EU 1005/2009)

###### Explosives Precursors Regulation (2019/1148)

Contains no substance(s) listed on the Explosives Precursors list (Regulation EU 2019/1148 on the marketing and use of explosives precursors)

###### Drug Precursors Regulation (273/2004)

Contains no substance(s) listed on the Drug Precursors list (Regulation EC 273/2004 on the manufacture and the placing on market of certain substances used in the illicit manufacture of narcotic drugs and psychotropic substances)

##### 15.1.2. National regulations

No additional information available

#### 15.2. Chemical safety assessment

No additional information available

### SECTION 16: Other information

#### Full text of H- and EUH-statements:

H336	May cause drowsiness or dizziness.
H361	Suspected of damaging fertility or the unborn child.
H362	May cause harm to breast-fed children.
Lact.	Reproductive toxicity, Additional category, Effects on or via lactation
Repr. 2	Reproductive toxicity, Category 2
STOT SE 3	Specific target organ toxicity – Single exposure, Category 3, Narcosis

Safety Data Sheet (SDS), EU

**DISCLAIMER OF LIABILITY** The EDQM has created this SDS as a downstream user for regulatory compliance to rules applicable to chemicals only. This article is intended only for small-volume laboratory analysis and other routine testing prescribed in the pharmacopoeia or EDQM study protocol, under controlled conditions and by professionals only. Any other use of this article or the SDS information is the sole responsibility of the user. This substance is present in articles in quantities totalling under 10 kg per year. There is no human or environmental exposure under intended and foreseeable conditions of use. The user has the responsibility for handling, storage, use conditions and disposal of this article and for any use of the information in this SDS. The information has been obtained from suppliers and is without any warranty, express or implied, regarding its correctness. For this and other reasons, we do not assume responsibility and expressly disclaim liability for loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of the article.